{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:01:56Z","timestamp":1772748116172,"version":"3.50.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Although a phase 3 trial did not demonstrate a survival benefit for gemcitabine, cisplatin, and nab-paclitaxel (Gem\/Cis\/Nab-P) in advanced biliary tract cancer (BTC), favorable outcomes were observed in specific patient subgroups, notably those with locally advanced disease or gallbladder carcinoma (GBC). This study aimed to assess the prognostic value of FDG PET\/CT-derived parameters in advanced BTC patients treated with the Gem\/Cis\/Nab-P regimen, thereby identifying potential PET\/CT imaging biomarkers that may aid in predicting survival benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of 125 advanced BTC patients who underwent pretreatment FDG PET\/CT followed by Gem\/Cis\/Nab-P therapy. From the PET\/CT images, maximum standardized uptake value, metabolic tumor volume, and total lesion glycolysis (TLG) of primary tumors were quantified. The influence of these parameters on prognostic outcomes was determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Multivariate survival analysis identified TLG as an independent significant prognostic factor for both progression-free survival (PFS) and overall survival (OS) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.05). In subgroup analyses stratified by disease stage and TLG, patients with locally advanced disease and low TLG achieved the most favorable survival outcomes (median PFS, 18.4 months; median OS, not reached). Among tumor subtypes, TLG effectively differentiated PFS and OS in GBC patients, with the low TLG group exhibiting a median PFS of 11.7 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>TLG on pretreatment FDG PET\/CT served as an independent prognostic biomarker for PFS and OS in advanced BTC. Locally advanced disease and low TLG, as well as GBC with low TLG, might be predictive of enhanced survival benefit from Gem\/Cis\/Nab-P therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006306","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T17:00:24Z","timestamp":1770051624000},"page":"285-293","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Value of FDG PET\/CT Parameters in Patients With Advanced Biliary Tract Cancer Receiving Gemcitabine, Cisplatin, and Nab-Paclitaxel"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2697-3578","authenticated-orcid":false,"given":"Jeong Won","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Soonchunhyang University Cheonan Hospital, Cheonan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7943-3807","authenticated-orcid":false,"given":"Sang Mi","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Soonchunhyang University Cheonan Hospital, Cheonan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5177-8937","authenticated-orcid":false,"given":"Beodeul","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1132-5217","authenticated-orcid":false,"given":"Jung Sun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8399-8456","authenticated-orcid":false,"given":"Jung Eun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, College of Medicine, Soonchunhyang University Cheonan Hospital, Cheonan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6979-5812","authenticated-orcid":false,"given":"Hong Jae","family":"Chon","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6103-6830","authenticated-orcid":false,"given":"Su Jin","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongam, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"R1-20260305","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"R2-20260305","doi-asserted-by":"crossref","first-page":"101171","DOI":"10.1016\/j.lanepe.2024.101171","article-title":"Mapping the landscape of biliary tract cancer in Europe: challenges and controversies","volume":"50","author":"Rimassa","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"R3-20260305","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R4-20260305","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"R5-20260305","doi-asserted-by":"crossref","first-page":"555","DOI":"10.5582\/bst.2024.01376","article-title":"First-line systemic therapy and sequencing options in advanced biliary tract cancer: a systematic review and network meta-analysis","volume":"18","author":"Xu","year":"2025","journal-title":"Biosci Trends"},{"key":"R6-20260305","doi-asserted-by":"crossref","first-page":"101290","DOI":"10.1016\/j.jhepr.2024.101290","article-title":"Recent advances in systemic therapy for advanced biliary tract cancer: a systematic review and meta-analysis using reconstructed RCT survival data","volume":"7","author":"Li","year":"2025","journal-title":"JHEP Rep"},{"key":"R7-20260305","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol"},{"key":"R8-20260305","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1245\/s10434-023-13809-5","article-title":"NEO-GAP: a single-arm, phase II feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma","volume":"30","author":"Maithel","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"R9-20260305","doi-asserted-by":"crossref","first-page":"602","DOI":"10.4143\/crt.2023.726","article-title":"A single-arm phase II study of nab-paclitaxel plus gemcitabine and cisplatin for locally advanced or metastatic biliary tract cancer","volume":"56","author":"Liu","year":"2024","journal-title":"Cancer Res Treat"},{"key":"R10-20260305","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO-24-01383","article-title":"SWOG S1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"43","author":"Shroff","year":"2025","journal-title":"J Clin Oncol"},{"key":"R11-20260305","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.surg.2022.09.028","article-title":"Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma","volume":"173","author":"Choi","year":"2023","journal-title":"Surgery"},{"key":"R12-20260305","doi-asserted-by":"crossref","first-page":"e20932","DOI":"10.1097\/MD.0000000000020932","article-title":"Comparison of magnetic resonance imaging and 18-fludeoxyglucose positron emission tomography\/computed tomography in the diagnostic accuracy of staging in patients with cholangiocarcinoma: a meta-analysis","volume":"99","author":"Huang","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R13-20260305","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/MNM.0000000000001405","article-title":"Impact of fluorine-18-fluorodeoxyglucose PET\/computed tomography in staging of patients with gallbladder cancer: a systematic review and meta-analysis","volume":"42","author":"Parida","year":"2021","journal-title":"Nucl Med Commun"},{"key":"R14-20260305","doi-asserted-by":"crossref","first-page":"684","DOI":"10.21037\/hbsn-21-25","article-title":"The influence of (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography on the N- and M-staging and subsequent clinical management of intrahepatic cholangiocarcinoma","volume":"11","author":"Lin","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"R15-20260305","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12967-018-1475-x","article-title":"Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by (18)F-FDG-PET is associated with the KRAS mutation status and prognosis","volume":"16","author":"Ikeno","year":"2018","journal-title":"J Transl Med"},{"key":"R16-20260305","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3892\/ol.2023.13711","article-title":"(18)F\u2011fluorodeoxyglucose positron emission tomography predicts recurrence and histological grade of extrahepatic bile duct cancer","volume":"25","author":"Yachi","year":"2023","journal-title":"Oncol Lett"},{"key":"R17-20260305","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jhbp.1421","article-title":"Total lesion glycolysis by (18)F-fluorodeoxyglucose positron emission tomography predicts tumor aggressiveness in patients with extrahepatic bile duct carcinoma","volume":"31","author":"Fukushima","year":"2024","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"R18-20260305","doi-asserted-by":"crossref","first-page":"971","DOI":"10.21873\/anticanres.13201","article-title":"Impact of metabolic parameters of (18)F-fluorodeoxyglucose positron-emission tomography after hepatic resection in patients with intrahepatic cholangiocarcinoma","volume":"39","author":"Harimoto","year":"2019","journal-title":"Anticancer Res"},{"key":"R19-20260305","doi-asserted-by":"crossref","first-page":"604","DOI":"10.21037\/qims-23-1003","article-title":"Metabolic parameters of pretreatment 2-[(18)F]fluoro-D-glucose positron emission tomography for prognosis in patients with gallbladder adenocarcinoma: a cohort study","volume":"14","author":"Li","year":"2024","journal-title":"Quant Imaging Med Surg"},{"key":"R20-20260305","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R21-20260305","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","article-title":"LIFEx: A freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity","volume":"78","author":"Nioche","year":"2018","journal-title":"Cancer Res"},{"key":"R22-20260305","first-page":"6985","article-title":"Prognostic value of FDG-PET\/CT total lesion glycolysis for patients with resectable distal bile duct adenocarcinoma","volume":"35","author":"Lee","year":"2015","journal-title":"Anticancer Res"},{"key":"R23-20260305","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s13139-012-0147-7","article-title":"Prognostic significance of volume-based metabolic parameters by (18)F-FDG PET\/CT in gallbladder carcinoma","volume":"46","author":"Yoo","year":"2012","journal-title":"Nucl Med Mol Imaging"},{"key":"R24-20260305","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00268-017-4192-3","article-title":"Diagnostic and prognostic role of 18-FDG PET\/CT in the management of resectable biliary tract cancer","volume":"42","author":"Ma","year":"2018","journal-title":"World J Surg"},{"key":"R25-20260305","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3348\/kjr.2019.0891","article-title":"Diagnostic performance and prognostic relevance of FDG positron emission tomography\/computed tomography for patients with extrahepatic cholangiocarcinoma","volume":"21","author":"Kim","year":"2020","journal-title":"Korean J Radiol"},{"key":"R26-20260305","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3349\/ymj.2019.60.7.604","article-title":"Significance of metabolic tumor volume and total lesion glycolysis measured using \u00b9\u2078F-FDG PET\/CT in locally advanced and metastatic gallbladder carcinoma","volume":"60","author":"Chun","year":"2019","journal-title":"Yonsei Med J"},{"key":"R27-20260305","doi-asserted-by":"crossref","first-page":"17588359211035983","DOI":"10.1177\/17588359211035983","article-title":"Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis","volume":"13","author":"Cheon","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"R28-20260305","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12094-018-1926-0","article-title":"Differences on metabolic behavior between intra and extrahepatic cholangiocarcinomas at (18)F-FDG-PET\/CT: prognostic implication of metabolic parameters and tumor markers","volume":"21","author":"Sabat\u00e9-Llobera","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"R29-20260305","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s13139-018-0542-9","article-title":"Inverse prognostic relationships of (18)F-FDG PET\/CT metabolic parameters in patients with distal bile duct cancer undergoing curative surgery","volume":"52","author":"Yi","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"R30-20260305","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4166\/kjg.2013.62.4.227","article-title":"Primary tumor maximum standardized uptake value measured on 18F-fluorodeoxyglucose positron emission tomography-computed tomography is a prognostic value for survival in bile duct and gallbladder cancer","volume":"62","author":"Lee","year":"2013","journal-title":"Korean J Gastroenterol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:02:35Z","timestamp":1772744555000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006306","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"2025-07-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}